pimodivir
Small moleculeexperimental
Pimodivir is an antiviral drug which was developed as a treatment for influenza. It acts as an inhibitor of influenza virus polymerase basic protein 2, and has shown promising results in Phase II clinical trials. However, in late 2021, Janssen announced that the clinical development of pimidivir had been halted due to lack of benefit over standard of care. — Wikipedia
Clinical trial activity
16 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
12
Phase 2
3
Phase 3
2
Phase 4
0
Earliest trial started May 1, 2015 (NCT02448004)
Timeline
Indications
Mechanism of action
- Influenza A virusINHIBITOR
Influenza A virus inhibitor
- Polymerase basic protein 2INHIBITOR
Polymerase basic protein 2 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
O=C(O)[C@H]1C2CCC(CC2)[C@@H]1Nc1nc(-c2c[nH]c3ncc(F)cc23)ncc1F- Mol. weight
- 399.4 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaPimodivir ↗
- ChEMBLCHEMBL3318007 ↗
Also known as
- jnj-63623872
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03947814 | Phase 1 | Jun 24, 2019 | Johnson and Johnson |
| NCT03816631 | Phase 1 | May 28, 2019 | Johnson and Johnson |
| NCT03768609 | Phase 1 | Dec 6, 2018 | Johnson and Johnson |
| NCT03381196 | Phase 3 | Jan 18, 2018 | Johnson and Johnson |
| NCT03376321 | Phase 3 | Jan 3, 2018 | Johnson and Johnson |
| NCT03023852 | Phase 1 | Feb 14, 2017 | Johnson and Johnson |
| NCT02860806 | Phase 1 | Aug 8, 2016 | Johnson and Johnson |
| NCT02888327 | Phase 1 | Jul 31, 2016 | Alios BioPharma, Hammersmith Medicines Research |
| NCT02658825 | Phase 1 | Jan 1, 2016 | Johnson and Johnson |
| NCT02532283 | Phase 2 | Dec 11, 2015 | Johnson and Johnson |
| NCT02659735 | Phase 1 | Dec 1, 2015 | Johnson and Johnson |
| NCT02652650 | Phase 1 | Dec 1, 2015 | Johnson and Johnson |
| NCT02595268 | Phase 1 | Nov 1, 2015 | Johnson and Johnson |
| NCT02448004 | Phase 1 | May 1, 2015 | Janssen Pharmaceutica NV, Johnson and Johnson |
| NCT02418559 | Phase 1 | May 1, 2015 | Janssen Pharmaceutica NV, Johnson and Johnson |
| NCT03834376 | N/A | — | Johnson and Johnson |
Showing 16 of 16 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Johnson and Johnson | For profit | 15 | 15 | 4 | 2015 |
| Janssen Pharmaceutica NV | For profit | 2 | 0 | 1 | 2015 |
| Alios BioPharma | For profit | 1 | 1 | 1 | 2016 |
| Hammersmith Medicines Research | For profit | 1 | 0 | 1 | 2016 |
4 organizations
Page 1 / 1